Overview
As a direct and sole result of the outbreak of the coronavirus disease (COVID-19) and due to circumstances beyond our control, DIA has decided to change the format of the upcoming Global Labeling Conference from "face-to-face" (in-person) to entirely virtual.
For more information, please review the list of Frequently Asked Questions
April 20-21: Conference
DIA’s Global Labeling Conference is designed for professionals in medical product labeling and related disciplines as they work to develop and manage clear and accurate labeling information for the safe and effective use of prescription drugs, biologics, and medical devices. The efforts of these professionals are key to providing essential information needed by providers, patients, and payers to make decisions about product access, prescription, and use. Influences such as digital technology, patient centricity, evolving product classes, and changing regulations require the use of informed, systematic approaches throughout the labeling cycle to ensure the development and availability of current, compliant information in all regions where products are marketed.
This conference provides a forum for exchange among regulators and industry peers to update their knowledge of key local and global labeling policies and to examine the impact of changes on regulatory compliance. Most importantly, through interactive discussions with expert panels and peer-to-peer exchange, participants will share approaches, processes, and tools to ensure the availability of effective labeling content meeting the needs of patients, consumers, and prescribers.
Program Committee
-
Paula Hudson, RPh, RAC Director, Global Labeling
Eli Lilly and Company, United States -
Su-Yueh Lin Sr. Labeling Consultant, Regulatory Affairs
SYL Regulatory Consulting, Taiwan -
Deborah Bebbington Head Global Labeling
Bayer Plc, United Kingdom -
Theresa Brunone, MLS, MS Head-Labelling Compliance and Implementation, Global Labeling
GlaxoSmithKline, United States -
Barbara Lachmann, MD Sole Proprietor
Barbara Lachmann Labeling Consulting, Germany -
Megann Looker Executive Director, Head of Global Labeling
Jazz Pharmaceuticals, United Kingdom -
Rie Matsui, RPh Senior Director, Regional Labeling Head for APAC, International Labeling
Pfizer R&D Japan G.K., Japan -
Gerrit Nijveldt, MSc Global Labeling Consultant
Opus Regulatory Inc., United States -
Hayley Parker, PhD, MSc Vice President Regulatory Affairs
PepGen, United States -
Steven Bass, PhD President
Bass Biopharm Consulting Group LLC, United States -
A. Leander Fontaine, MD President
Pharmiceutics, LLC., United States
Have an account?